Clinical Commander

Back to dossier
cardio.hypertensive-emergency.nsaid-induced.v1PRODUCTION
cardio.hypertensive-emergency.nsaid-induced.v1

NSAID-induced hypertensive crisis (severe HTN driven by COX-1/COX-2 inhibition from indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, or celecoxib — most severe in CKD, HF, elderly, cirrhosis, or with concurrent ACEi/ARB/diuretic via "triple whammy" mechanism causing AKI; aspirin LESS implicated at low cardiovascular dose 81 mg/d)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

NSAID-induced HTN crisis = COX inhibition → reduced prostaglandin → loss of renal afferent vasodilation + reduced natriuresis + RAAS upregulation + Na+/water retention + endothelial vasoconstriction → severe HTN. Most vulnerable: CKD, HF, elderly, cirrhosis, on ACEi/ARB/diuretic ("triple whammy" → AKI). Pharmacology pivot: STOP NSAID immediately + IV nicardipine first-line for BP control + FUROSEMIDE 20-40 mg IV (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct. Long-term: AVOID NSAIDs in vulnerable patients; substitute acetaminophen (1 g q6h max 3-4 g/d), topical NSAID (minimal systemic), duloxetine for chronic musculoskeletal, opioid for severe with caution, gabapentinoid for neuropathic, intra-articular steroid for joint-specific. Route to parent engine for shared HTN-emergency arc; this dossier owns NSAID-specific pharmacology + triple-whammy AKI prevention.

Inputs
5
Actions
0
Advance rule
Set
Advance when

NSAID-induced etiology confirmed (med history + dose + duration + electrolyte/renal pattern)

Patient inputs (13)

Elderly (>65) most vulnerable due to age-related renal function decline + polypharmacy; pediatric NSAID exposure (chronic ibuprofen for JIA) less HTN-prone but still possible

Confirms etiology: drug name (indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, celecoxib, meloxicam, sulindac), dose, route (PO/IV/topical), duration, indication (musculoskeletal, RA, OA, headache, gout, dysmenorrhea, post-op analgesia), prescription vs OTC source; high-dose aspirin >1 g/d also causes HTN (low-dose 81 mg cardiovascular dose does not)

Triple whammy combination (NSAID + ACEi/ARB + diuretic) → markedly elevated AKI risk (Lapi BMJ 2013 RR 1.31) + worsened HTN response; check for vulnerable comorbidities (CKD, HF, cirrhosis, elderly)

Baseline + acute change: AKI from prostaglandin loss in vulnerable patients; eGFR drives nicardipine + furosemide dosing; KDIGO 2024 AKI criteria for staging

HyperK common from NSAID + ACEi/ARB combination (NSAID inhibits prostaglandin → reduced renin → reduced aldosterone → K retention); occasional hypoK if loop diuretic dominant

Hyponatremia possible from NSAID-induced ADH augmentation + impaired free-water excretion

Often coexists with electrolyte abnormalities; replace before K replacement effective if hypoK

LVH from chronic HTN; arrhythmia from electrolyte abnormalities; demand ischemia from severe HTN

Demand ischemia rule-out (Type 2 MI in elderly with CAD + severe HTN); baseline since NSAIDs (especially COX-2) have CV event risk

Severe HTN can cause hypertensive encephalopathy + ICH; focal deficit → STAT CT head

Defines crisis threshold ≥180; drives titration of nicardipine + furosemide; NSAID-induced HTN often resistant to RAAS blockade alone (NSAID neutralizes RAAS-blocking effect)

Component of MAP; DBP >120 supports crisis criterion; volume overload often elevates SBP > DBP (wide pulse pressure)

Often normal or mildly elevated (volume + RAAS-driven HTN, not catecholamine-driven)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningtriple_whammy_AKI_requiring_dialysis
    Triple whammy (NSAID + ACEi/ARB + diuretic) → severe AKI with uremia, hyperK >6, acidosis, or volume overload refractory to diuresis → dialysis indication (KDIGO 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningGI_bleed_on_NSAID_with_anticoagulant_or_antiplatelet
    NSAID + anticoagulant or antiplatelet → severe GI bleed (hematemesis, melena, dropping Hb) — high mortality combination especially in elderly
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningCV_event_on_selective_COX-2_celecoxib
    New MI, stroke, or CV death in patient on selective COX-2 (celecoxib, etoricoxib) — class CV event signal per Solomon Circulation 2008 PMID 18506014
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_NSAID_exposure_error
    Patient with prior NSAID-induced HTN crisis re-exposed to NSAID via OTC purchase, prescription error, or unknown ingestion (e.g., combination cold/flu remedy) — system + patient education failure
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

NSAID-induced HTN crisis — STOP NSAID + IV nicardipine + FUROSEMIDE (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct + IV fluids if prerenal AKI + alternative pain regimen (acetaminophen, topical, duloxetine, opioid + multimodal, gabapentinoid, intra-articular steroid) + NSAID-avoid alert + triple-whammy prevention
axis: nsaid_induced_htn_crisis_pharmacology
Selected axis "NSAID-induced HTN crisis — STOP NSAID + IV nicardipine + FUROSEMIDE (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct + IV fluids if prerenal AKI + alternative pain regimen (acetaminophen, topical, duloxetine, opioid + multimodal, gabapentinoid, intra-articular steroid) + NSAID-avoid alert + triple-whammy prevention" by default fallback (first axis)
  • nicardipine
    first line
    dihydropyridine_ccb
    5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h • IV • continuous infusion
    triggers: nsaid_induced_HTN_crisis_confirmed
    AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded NSAID patients
    rxcui 7396
  • furosemide
    first line
    loop_diuretic
    20-40 mg IV (higher doses 80-160 mg if CKD or HF; double dose if no UOP response within 30 min) • IV • q6-12h or continuous infusion
    triggers: nsaid_induced_HTN_with_volume_overload, pulmonary_edema
    Whelton AJM 2000 + KDIGO 2024 — overcomes renal Na+ retention from NSAID-induced prostaglandin loss; loop diuretic remains effective even in NSAID-blunted natriuresis (acts proximal to prostaglandin-dependent step); first-line for volume overload in NSAID HTN
    rxcui 4603
  • labetalol
    second line
    mixed_alpha_beta_blocker
    10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min • IV • PRN bolus or continuous
    triggers: persistent_HTN_after_nicardipine_and_furosemide
    Mixed α/β safe in NSAID-induced HTN; standard HTN-emergency adjunct per AHA 2025
    rxcui 6185
  • spironolactone
    comorbidity specific
    mineralocorticoid_receptor_antagonist
    25-50 mg PO daily • PO • daily
    triggers: hypokalemia_from_loop_diuretic, concurrent_resistant_HTN_phenotype
    Adjunct if hypoK from loop diuretic; CONTRAINDICATED if hyperK from NSAID + ACEi triple whammy
    rxcui 9997
  • potassium chloride
    comorbidity specific
    electrolyte
    KCl 40 mEq PO TID OR 10-20 mEq IV/h to target K 4-5 • PO + IV • PRN
    triggers: hypokalemia_K_below_3.5_from_loop_diuretic
    Replacement if loop diuretic dominant + hypoK; AVOID if hyperK from triple whammy
    rxcui 8591
  • magnesium sulfate
    comorbidity specific
    electrolyte
    2-4 g IV • IV • PRN to target Mg 2.0-2.5
    triggers: hypomagnesemia_Mg_below_2.0
    Often coexists with hypoK; correct before K replacement effective
    rxcui 6585
  • acetaminophen
    first line
    non_nsaid_analgesic
    1 g PO/IV q6h (max 3-4 g/d; max 2 g/d if cirrhosis or chronic alcohol use) • PO/IV • q6h
    triggers: need_alternative_to_NSAID_for_pain
    First-line NSAID alternative for general pain; minimal cardiovascular + renal risk; max dose limit critical in liver dysfunction
    rxcui 161
  • topical diclofenac gel (1% or 2%)
    second line
    topical_nsaid_minimal_systemic
    2-4 g topical q6-8h to affected area • topical • q6-8h
    triggers: localized_musculoskeletal_pain_no_systemic_NSAID_safe
    ACR 2020 Hochberg — topical NSAID has minimal systemic absorption; reasonable for localized MSK pain in NSAID-vulnerable patients (still some systemic exposure — use cautiously and monitor BP)
    rxcui 3355
  • duloxetine
    comorbidity specific
    snri_chronic_pain
    30 mg PO daily × 1 week then 60 mg PO daily • PO • daily
    triggers: chronic_musculoskeletal_pain, fibromyalgia, chronic_low_back_pain
    ACR 2020 + AHRQ 2020 chronic pain guidelines — SNRI proven for chronic MSK pain (knee OA, low back pain, fibromyalgia); cardiovascular-neutral; reasonable NSAID alternative for chronic conditions
    rxcui 72625
  • lidocaine 5% patch
    second line
    topical_anesthetic
    1-3 patches to affected area for up to 12h on / 12h off • topical • q12h on/off
    triggers: localized_neuropathic_or_postherpetic_pain, localized_MSK_pain
    Minimal systemic absorption; topical analgesia for localized pain; good NSAID alternative
    rxcui 6387
  • gabapentin
    comorbidity specific
    gabapentinoid_neuropathic
    100-300 mg PO TID titrate (max 3600 mg/d; reduce in CKD) • PO • TID
    triggers: neuropathic_pain, diabetic_neuropathy, postherpetic_neuralgia
    AAN 2022 + ADA 2026 — first-line for neuropathic pain; reduce dose in CKD; cardiovascular-neutral
    rxcui 25480
  • tramadol
    second line
    mixed_opioid_snri
    50-100 mg PO q4-6h (max 400 mg/d; reduce in elderly + CKD) • PO • q4-6h
    triggers: moderate_acute_pain_with_NSAID_contraindicated
    Less potent opioid; safer than full opioid for moderate pain; risk of serotonin syndrome with serotonergic agents + lowers seizure threshold
    rxcui 10689
  • morphine
    second line
    opioid
    2-4 mg IV q3-4h or 15 mg PO q4-6h (lowest effective dose, multimodal) • IV/PO • PRN with stewardship
    triggers: severe_acute_pain_short_course, palliative_chronic_pain
    Reserve for severe acute pain unrelieved by alternatives; opioid stewardship critical (limit duration, lowest dose, naloxone co-prescribing for chronic users); avoid for chronic pain when possible
    rxcui 7052
  • intra-articular methylprednisolone or triamcinolone
    second line
    intra_articular_glucocorticoid
    Methylprednisolone 40-80 mg or triamcinolone 20-40 mg per joint • intra-articular • q3-6 months
    triggers: localized_joint_pain_OA_or_inflammatory_arthritis
    ACR 2020 Hochberg — minimal systemic absorption; effective for joint-specific pain; cardiovascular-neutral
    rxcui 5640
  • STOP NSAID IMMEDIATELY (any route)
    first line
    first_line_intervention
    Discontinue all NSAID exposure • N/A • N/A
    triggers: nsaid_induced_HTN_crisis
    Mechanism-targeted — removing the offending agent reverses prostaglandin inhibition + RAAS upregulation; PO + IV + topical (latter has some absorption); Curhan 2002 + Aw meta — improvement within days of cessation in most patients
  • AVOID NSAIDs in CKD, HF, elderly, cirrhosis, on ACEi/ARB/diuretic (TRIPLE WHAMMY)
    contraindication substitute
    avoid_combination
    AVOID • N/A • N/A
    triggers: high_risk_population_for_NSAID_complications
    Lapi BMJ 2013 PMID 23299844 — triple whammy (NSAID + ACEi + diuretic) RR 1.31 for AKI; KDIGO 2024 — NSAID-AVOID in CKD; ACC/AHA 2025 — NSAID-AVOID in HF; ACR 2020 — caution in elderly; substitute alternative pain regimen
  • NSAID-AVOID alert documented in chart + medication list
    add on
    prevention_protocol
    Documented as allergy/intolerance with rationale "drug-induced HTN crisis" • documentation • permanent
    triggers: nsaid_induced_HTN_crisis_resolved
    Prevents future inadvertent NSAID exposure; PCP + pharmacy + family + patient education; medical-alert bracelet for chronic vulnerability (CKD, HF)
  • OTC NSAID counseling — identify hidden sources
    add on
    patient_education
    Education on OTC ibuprofen, naproxen, aspirin >1 g, combination products (Excedrin, Aleve PM, cold/flu remedies) • education • ongoing
    triggers: nsaid_induced_HTN_crisis
    Patients often unaware OTC products contain NSAIDs; pharmacy + caregiver involvement; alternative OTC: acetaminophen for pain, antihistamine for cold without ibuprofen

outpatient playbook — drug actions (3)

  1. 1. continue PO antihypertensive regimen
    rxcui 17767
    Amlodipine + chlorthalidone ± lisinopril • PO • daily
    trigger: Sustained HTN control
    ACC/AHA 2025 4-tier ladder
  2. 2. continue alternative pain regimen
    rxcui 161
    Acetaminophen + topical + duloxetine + gabapentin per etiology • PO + topical • scheduled
    trigger: Continued pain control
    NSAID-sparing chronic management
  3. 3. consider non-pharmacologic pain modalities
    Physical therapy + weight loss for OA + joint replacement consult if severe + intra-articular steroid q3-6 mo + acupuncture + cognitive behavioral therapy • multiple • as scheduled
    trigger: Chronic pain optimization
    ACR 2020 multimodal

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Chronic or high-dose NSAID exposure (indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, celecoxib) with new SBP ≥180 / DBP ≥120 — typically days-to-weeks of exposure precipitates in vulnerable patients (Curhan 2002 + Aw meta); Triple whammy: NSAID + ACEi/ARB + diuretic combination → severe HTN + AKI (Lapi BMJ 2013 PMID 23299844 — RR 1.31 for AKI) — classic outpatient elderly presentation; Self-medication with OTC NSAID (ibuprofen, naproxen) for back pain, headache, or arthritis without prescriber awareness — common preventable cause.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**NSAID-induced hypertensive crisis (severe HTN driven by COX-1/COX-2 inhibition from indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, or celecoxib — most severe in CKD, HF, elderly, cirrhosis, or with concurrent ACEi/ARB/diuretic via "triple whammy" mechanism causing AKI; aspirin LESS implicated at low cardiovascular dose 81 mg/d)** (cardio.hypertensive-emergency.nsaid-induced.v1).
Scope: NSAID-induced HTN crisis = COX inhibition → reduced prostaglandin → loss of renal afferent vasodilation + reduced natriuresis + RAAS upregulation + Na+/water retention + endothelial vasoconstriction → severe HTN. Most vulnerable: CKD, HF, elderly, cirrhosis, on ACEi/ARB/diuretic ("triple whammy" → AKI). Pharmacology pivot: STOP NSAID immediately + IV nicardipine first-line for BP control + FUROSEMIDE 20-40 mg IV (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct. Long-term: AVOID NSAIDs in vulnerable patients; substitute acetaminophen (1 g q6h max 3-4 g/d), topical NSAID (minimal systemic), duloxetine for chronic musculoskeletal, opioid for severe with caution, gabapentinoid for neuropathic, intra-articular steroid for joint-specific. Route to parent engine for shared HTN-emergency arc; this dossier owns NSAID-specific pharmacology + triple-whammy AKI prevention.

No severity triggers fired against current inputs.

Plan

Regimen axis: **NSAID-induced HTN crisis — STOP NSAID + IV nicardipine + FUROSEMIDE (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct + IV fluids if prerenal AKI + alternative pain regimen (acetaminophen, topical, duloxetine, opioid + multimodal, gabapentinoid, intra-articular steroid) + NSAID-avoid alert + triple-whammy prevention**.
1. nicardipine 5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h IV continuous infusion (dihydropyridine_ccb, first line) — AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded NSAID patients
2. furosemide 20-40 mg IV (higher doses 80-160 mg if CKD or HF; double dose if no UOP response within 30 min) IV q6-12h or continuous infusion (loop_diuretic, first line) — Whelton AJM 2000 + KDIGO 2024 — overcomes renal Na+ retention from NSAID-induced prostaglandin loss; loop diuretic remains effective even in NSAID-blunted natriuresis (acts proximal to prostaglandin-dependent step); first-line for volume overload in NSAID HTN
3. labetalol 10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min IV PRN bolus or continuous (mixed_alpha_beta_blocker, second line) — Mixed α/β safe in NSAID-induced HTN; standard HTN-emergency adjunct per AHA 2025
4. spironolactone 25-50 mg PO daily PO daily (mineralocorticoid_receptor_antagonist, comorbidity specific) — Adjunct if hypoK from loop diuretic; CONTRAINDICATED if hyperK from NSAID + ACEi triple whammy
5. potassium chloride KCl 40 mEq PO TID OR 10-20 mEq IV/h to target K 4-5 PO + IV PRN (electrolyte, comorbidity specific) — Replacement if loop diuretic dominant + hypoK; AVOID if hyperK from triple whammy
6. magnesium sulfate 2-4 g IV IV PRN to target Mg 2.0-2.5 (electrolyte, comorbidity specific) — Often coexists with hypoK; correct before K replacement effective
7. acetaminophen 1 g PO/IV q6h (max 3-4 g/d; max 2 g/d if cirrhosis or chronic alcohol use) PO/IV q6h (non_nsaid_analgesic, first line) — First-line NSAID alternative for general pain; minimal cardiovascular + renal risk; max dose limit critical in liver dysfunction
8. topical diclofenac gel (1% or 2%) 2-4 g topical q6-8h to affected area topical q6-8h (topical_nsaid_minimal_systemic, second line) — ACR 2020 Hochberg — topical NSAID has minimal systemic absorption; reasonable for localized MSK pain in NSAID-vulnerable patients (still some systemic exposure — use cautiously and monitor BP)
9. duloxetine 30 mg PO daily × 1 week then 60 mg PO daily PO daily (snri_chronic_pain, comorbidity specific) — ACR 2020 + AHRQ 2020 chronic pain guidelines — SNRI proven for chronic MSK pain (knee OA, low back pain, fibromyalgia); cardiovascular-neutral; reasonable NSAID alternative for chronic conditions
10. lidocaine 5% patch 1-3 patches to affected area for up to 12h on / 12h off topical q12h on/off (topical_anesthetic, second line) — Minimal systemic absorption; topical analgesia for localized pain; good NSAID alternative
11. gabapentin 100-300 mg PO TID titrate (max 3600 mg/d; reduce in CKD) PO TID (gabapentinoid_neuropathic, comorbidity specific) — AAN 2022 + ADA 2026 — first-line for neuropathic pain; reduce dose in CKD; cardiovascular-neutral
12. tramadol 50-100 mg PO q4-6h (max 400 mg/d; reduce in elderly + CKD) PO q4-6h (mixed_opioid_snri, second line) — Less potent opioid; safer than full opioid for moderate pain; risk of serotonin syndrome with serotonergic agents + lowers seizure threshold
13. morphine 2-4 mg IV q3-4h or 15 mg PO q4-6h (lowest effective dose, multimodal) IV/PO PRN with stewardship (opioid, second line) — Reserve for severe acute pain unrelieved by alternatives; opioid stewardship critical (limit duration, lowest dose, naloxone co-prescribing for chronic users); avoid for chronic pain when possible
14. intra-articular methylprednisolone or triamcinolone Methylprednisolone 40-80 mg or triamcinolone 20-40 mg per joint intra-articular q3-6 months (intra_articular_glucocorticoid, second line) — ACR 2020 Hochberg — minimal systemic absorption; effective for joint-specific pain; cardiovascular-neutral
15. STOP NSAID IMMEDIATELY (any route) Discontinue all NSAID exposure N/A N/A (first_line_intervention, first line) — Mechanism-targeted — removing the offending agent reverses prostaglandin inhibition + RAAS upregulation; PO + IV + topical (latter has some absorption); Curhan 2002 + Aw meta — improvement within days of cessation in most patients
16. AVOID NSAIDs in CKD, HF, elderly, cirrhosis, on ACEi/ARB/diuretic (TRIPLE WHAMMY) AVOID N/A N/A (avoid_combination, contraindication substitute) — Lapi BMJ 2013 PMID 23299844 — triple whammy (NSAID + ACEi + diuretic) RR 1.31 for AKI; KDIGO 2024 — NSAID-AVOID in CKD; ACC/AHA 2025 — NSAID-AVOID in HF; ACR 2020 — caution in elderly; substitute alternative pain regimen
17. NSAID-AVOID alert documented in chart + medication list Documented as allergy/intolerance with rationale "drug-induced HTN crisis" documentation permanent (prevention_protocol, add on) — Prevents future inadvertent NSAID exposure; PCP + pharmacy + family + patient education; medical-alert bracelet for chronic vulnerability (CKD, HF)
18. OTC NSAID counseling — identify hidden sources Education on OTC ibuprofen, naproxen, aspirin >1 g, combination products (Excedrin, Aleve PM, cold/flu remedies) education ongoing (patient_education, add on) — Patients often unaware OTC products contain NSAIDs; pharmacy + caregiver involvement; alternative OTC: acetaminophen for pain, antihistamine for cold without ibuprofen

Setting playbook (outpatient) — Long-term PCP + nephrology + pain medicine coordination — sustained BP <130/80, full AKI recovery (or stable post-AKI baseline), permanent NSAID-AVOID alert, alternative multimodal pain regimen, periodic OTC NSAID counseling reinforcement
19. continue PO antihypertensive regimen Amlodipine + chlorthalidone ± lisinopril PO daily — Sustained HTN control (ACC/AHA 2025 4-tier ladder)
20. continue alternative pain regimen Acetaminophen + topical + duloxetine + gabapentin per etiology PO + topical scheduled — Continued pain control (NSAID-sparing chronic management)
21. consider non-pharmacologic pain modalities Physical therapy + weight loss for OA + joint replacement consult if severe + intra-articular steroid q3-6 mo + acupuncture + cognitive behavioral therapy multiple as scheduled — Chronic pain optimization (ACR 2020 multimodal)

Non-pharmacologic actions:
- 90-day fill auto-refill confirmed annually + NSAID-AVOID pharmacy alert active
- Medication card in wallet (NSAID-AVOID — drug-induced HTN crisis)
- Annual NSAID-AVOID counseling reinforcement
- OTC NSAID identification education at every visit
- Family + caregiver involvement in NSAID-avoidance
- Annual flu vaccine + age-appropriate vaccines
- Lifestyle counseling (DASH diet, exercise, sleep, weight loss for OA)

AVOID / contraindication checks:
- NSAID_AVOID_in_CKD_HF_elderly_cirrhosis_or_on_ACEi_ARB_diuretic_triple_whammy (Lapi BMJ 2013 PMID 23299844; KDIGO 2024; ACC/AHA 2025)
- NSAID_AVOID_with_anticoagulant_or_antiplatelet (additive GI bleed risk)
- Topical_NSAID_caution_in_NSAID_AVOID_patients (still some systemic absorption — monitor BP)
- Acetaminophen_max_3 4_g_per_day_max_2_g_if_cirrhosis_or_chronic_alcohol_use
- Hold_ACEi_ARB_acutely_if_AKI_or_hyperK_from_triple_whammy_resume_when_renal_function_stabilizes
- Spironolactone_AVOID_if_hyperK_above_5.5_from_triple_whammy
- Opioid_stewardship_for_NSAID_alternative_lowest_dose_shortest_duration_naloxone_for_chronic_users
- Tramadol_caution_with_serotonergic_agents_serotonin_syndrome_risk_and_seizure_threshold
- Gabapentin_dose_reduce_in_CKD_per_eGFR_KDIGO_2024
- Topical_lidocaine_avoid_with_class_I_antiarrhythmics
- Selective_COX 2_celecoxib_class_CV_event_risk_per_Solomon_Circulation_2008_PMID_18506014
- NSAID_AVOID_alert_documented_in_chart_after_crisis

Monitoring

Regimen monitoring:
- continuous ECG q15min BP minimum 24h (AHA 2025 HTN)
- q4-6h BMP Mg until normalized
- daily creatinine and UOP for AKI tracking KDIGO 2024
- daily weight for volume status
- serial neuro exam q2h x 12h for encephalopathy or ICH
- GI bleed surveillance Hb BUN stool guaiac if concern
- home BP log weekly during recovery then monthly
- pain scale assessment with alternative regimen
- PCP visit at 1 week post d/c for BP recheck and alternative regimen titration
- nephrology follow-up at 1-2 weeks for post-AKI surveillance
- pharmacy review for NSAID-AVOID alert
- eGFR re-establishment at 3 months post-AKI

Setting (outpatient) monitoring:
- Quarterly BP
- Annual ECG + lipid + A1c + eGFR
- Pain scale + adherence + alternative regimen verification
- Annual NSAID-AVOID alert verification in pharmacy + chart + medication card

Follow-up plan: NSAID-AVOIDANCE COUNSELING: comprehensive education on NSAID risks for patient + family + caregivers + PCP + pharmacy team; identify all OTC sources (ibuprofen, naproxen, aspirin >1 g, combination products); MEDICATION-LIST DOCUMENTATION: "NSAID-AVOID" added to allergy list with rationale; ALTERNATIVE PAIN REGIMEN: acetaminophen 1 g PO q6h max 3-4 g/d for general pain (max 2 g/d if cirrhosis), topical NSAID (diclofenac gel, lidocaine patch — minimal systemic) for localized musculoskeletal, duloxetine 30-60 mg PO daily for chronic musculoskeletal, intra-articular steroid for joint-specific, gabapentinoid 100-300 mg TID for neuropathic, opioid for severe acute pain only with multimodal + opioid stewardship; PCP COORDINATION: weekly BP + BMP × 4 weeks then monthly during recovery; KIDNEY RECOVERY: nephrology follow-up in 1-2 weeks for post-AKI surveillance, baseline eGFR re-establishment (some never fully recover after triple-whammy AKI); CV RISK ASSESSMENT: if previously on selective COX-2 for chronic pain, reassess CV risk + consider class avoidance; ALL CARE TEAMS: pharmacy alert on chart "NSAID-AVOID — drug-induced HTN crisis"; PCP + cardiology + nephrology + pain medicine follow-up within 1-2 weeks
- Close-out criterion: NSAID-avoid alert documented + alternative pain regimen prescribed + PCP/cardiology/nephrology/pain medicine follow-up booked + patient + family education done

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP; q4-6h BMP + Mg until normalized; daily creatinine + UOP for AKI tracking; daily weight (volume status); serial neuro exam q2h × 12 h; pain scale assessment with alternative regimen; GI bleed surveillance (Hb, BUN, stool guaiac if concern)

Disposition

Current setting: outpatient — Long-term PCP + nephrology + pain medicine coordination — sustained BP <130/80, full AKI recovery (or stable post-AKI baseline), permanent NSAID-AVOID alert, alternative multimodal pain regimen, periodic OTC NSAID counseling reinforcement

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + cardio.htn.resistant.v1 for chronic management; cross-link to neph.ckd.core.v1 if post-AKI CKD

Escalation triggers (move to higher acuity):
- Recurrent HTN crisis → urgent visit + reassess regimen + verify no NSAID exposure (often reveals new OTC source)
- Inadvertent NSAID exposure → urgent visit + repeat education + re-establish alert in all systems
- AKI worsening over time → nephrology
- Inadequate pain control on alternatives → pain medicine specialty + interventional options

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Triple whammy (NSAID + ACEi/ARB + diuretic) → severe AKI with uremia, hyperK >6, acidosis, or volume overload refractory to diuresis → dialysis indication (KDIGO 2024)
- [LIFE_THREATENING] NSAID + anticoagulant or antiplatelet → severe GI bleed (hematemesis, melena, dropping Hb) — high mortality combination especially in elderly
- [LIFE_THREATENING] New MI, stroke, or CV death in patient on selective COX-2 (celecoxib, etoricoxib) — class CV event signal per Solomon Circulation 2008 PMID 18506014

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + KDIGO 2024 CKD/AKI + ACR 2020 Hochberg pain management + Lapi BMJ 2013 (PMID 23299844 triple-whammy AKI cohort) [PMID:23299844](https://pubmed.ncbi.nlm.nih.gov/23299844/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 10995087) [PMID:10995087](https://pubmed.ncbi.nlm.nih.gov/10995087/)
- Cited evidence (PMID 18506014) [PMID:18506014](https://pubmed.ncbi.nlm.nih.gov/18506014/)
- Cited evidence (PMID 11772122) [PMID:11772122](https://pubmed.ncbi.nlm.nih.gov/11772122/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + KDIGO 2024 CKD/AKI + ACR 2020 Hochberg pain management + Lapi BMJ 2013 (PMID 23299844 triple-whammy AKI cohort) — PMID:23299844
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 10995087) — PMID:10995087
  • Cited evidence (PMID 18506014) — PMID:18506014
  • Cited evidence (PMID 11772122) — PMID:11772122